517 related articles for article (PubMed ID: 16249547)
1. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.
Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
Diabetes Care; 2005 Nov; 28(11):2728-32. PubMed ID: 16249547
[TBL] [Abstract][Full Text] [Related]
2. Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria.
Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Koide H
Diabetes Metab Res Rev; 2006; 22(5):385-9. PubMed ID: 16506273
[TBL] [Abstract][Full Text] [Related]
3. Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease.
Yang X; Zhang B; Lu X; Yan M; Wen Y; Zhao T; Li P
BMC Complement Altern Med; 2016 Jul; 16():246. PubMed ID: 27460780
[TBL] [Abstract][Full Text] [Related]
4. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy.
Nakamura T; Sugaya T; Node K; Ueda Y; Koide H
Am J Kidney Dis; 2006 Mar; 47(3):439-44. PubMed ID: 16490622
[TBL] [Abstract][Full Text] [Related]
5. Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.
Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Inoue T; Node K
Am J Nephrol; 2006; 26(1):82-6. PubMed ID: 16534182
[TBL] [Abstract][Full Text] [Related]
6. Effect of erythropoietin on urinary liver-type fatty-acid-binding protein in patients with chronic renal failure and anemia.
Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H
Am J Nephrol; 2006; 26(3):276-80. PubMed ID: 16772708
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy.
Kimura S; Inoguchi T; Yokomizo H; Maeda Y; Sonoda N; Takayanagi R
Diabetes Obes Metab; 2012 Jul; 14(7):666-9. PubMed ID: 22268518
[TBL] [Abstract][Full Text] [Related]
8. Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes.
von Eynatten M; Baumann M; Heemann U; Zdunek D; Hess G; Nawroth PP; Bierhaus A; Humpert PM
Eur J Clin Invest; 2010 Feb; 40(2):95-102. PubMed ID: 19912308
[TBL] [Abstract][Full Text] [Related]
9. Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis.
Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
Clin Nephrol; 2006 Jan; 65(1):1-6. PubMed ID: 16429835
[TBL] [Abstract][Full Text] [Related]
10. Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy.
Nakamura T; Fujiwara N; Sugaya T; Ueda Y; Koide H
Metabolism; 2009 Aug; 58(8):1185-90. PubMed ID: 19481229
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients.
Kamijo-Ikemori A; Sugaya T; Yasuda T; Kawata T; Ota A; Tatsunami S; Kaise R; Ishimitsu T; Tanaka Y; Kimura K
Diabetes Care; 2011 Mar; 34(3):691-6. PubMed ID: 21273494
[TBL] [Abstract][Full Text] [Related]
12. Association of urinary liver-type fatty acid-binding protein with renal functions and antihyperglycemic drug use in type 2 diabetic nephropathy patients.
Hirowatari K; Kawano N
Int Urol Nephrol; 2023 Aug; 55(8):2111-2118. PubMed ID: 36840803
[TBL] [Abstract][Full Text] [Related]
13. Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.
Nakamura T; Fujiwara N; Sato E; Ueda Y; Sugaya T; Koide H
Kidney Blood Press Res; 2010; 33(3):213-20. PubMed ID: 20588058
[TBL] [Abstract][Full Text] [Related]
14. Urinary markers in the early stage of nephropathy in patients with childhood-onset type 1 diabetes.
Suh JS; Kim SH; Cho KS; Jung IA; Cho WK; Jeon YJ; Jung MH; Suh BK
Pediatr Nephrol; 2016 Apr; 31(4):623-31. PubMed ID: 26525196
[TBL] [Abstract][Full Text] [Related]
15. Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease.
Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
Am J Med Sci; 2005 Oct; 330(4):161-5. PubMed ID: 16234607
[TBL] [Abstract][Full Text] [Related]
16. Nonalbuminuric proteinuria as a biomarker for tubular damage in early development of nephropathy with type 2 diabetic patients.
Kim SS; Song SH; Kim IJ; Kim WJ; Jeon YK; Kim BH; Kwak IS; Lee EK; Kim YK
Diabetes Metab Res Rev; 2014 Nov; 30(8):736-41. PubMed ID: 24687388
[TBL] [Abstract][Full Text] [Related]
17. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET).
Inoue T; Ikeda H; Nakamura T; Abe S; Taguchi I; Kikuchi M; Toyoda S; Miyazono M; Kishi T; Sanai T; Node K
Intern Med; 2011; 50(12):1273-8. PubMed ID: 21673461
[TBL] [Abstract][Full Text] [Related]
18. Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy.
Araki S; Haneda M; Koya D; Sugaya T; Isshiki K; Kume S; Kashiwagi A; Uzu T; Maegawa H
Diabetes Care; 2013 May; 36(5):1248-53. PubMed ID: 23223350
[TBL] [Abstract][Full Text] [Related]
19. Level of urinary liver-type fatty acid-binding protein is associated with cardiac markers and electrocardiographic abnormalities in type-2 diabetes with chronic kidney disease stage G1 and G2.
Maeda Y; Suzuki A; Ishii J; Sekiguchi-Ueda S; Shibata M; Yoshino Y; Asano S; Hayakawa N; Nakamura K; Akiyama Y; Kitagawa F; Sakuishi T; Fujita T; Hashimoto S; Ozaki Y; Itoh M
Heart Vessels; 2015 May; 30(3):362-8. PubMed ID: 24626813
[TBL] [Abstract][Full Text] [Related]
20. Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy.
Hofstra JM; Deegens JK; Steenbergen EJ; Wetzels JF
Nephrol Dial Transplant; 2008 Oct; 23(10):3160-5. PubMed ID: 18403431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
